Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. BVS
BVS logo

BVS

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BVS News

Bioventus Q4 2025 Earnings Call Highlights

5d agoseekingalpha

Bioventus (BVS) Q4 2025 Earnings Call Transcript

5d agoNASDAQ.COM

Bioventus Reports Q4 2025 Financial Results with Strong Growth

5d agoNewsfilter

Bioventus Releases Financial Guidance for FY 2026

5d agoseekingalpha

Wall Street Analysts Adjust Ratings on Key Stocks

Feb 09 2026Benzinga

BIOVENTUS INC: BARRINGTON RESEARCH STARTS COVERAGE WITH OUTPERFORM RATING AND SETS PRICE TARGET AT $13

Feb 09 2026moomoo

Bravura Solutions Projects FY2026 Revenue of A$265-275 Million Amid Insider Buying

Jan 01 2026Yahoo Finance

BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO

Dec 11 2025Globenewswire

Halper Sadeh Investigates Bioventus for Potential Shareholder Compensation

Dec 05 2025PRnewswire

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

Jul 30 2025Newsfilter

Cantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12

Jul 07 2025Benzinga

Peek Under The Hood: FHLC Has 21% Upside

Jun 20 2025NASDAQ.COM

Canaccord Genuity Maintains Buy on Bioventus, Maintains $15 Price Target

Mar 17 2025Benzinga

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Mar 11 2025Benzinga

Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday

Mar 11 2025Benzinga

Bioventus reports Q4 non-GAAP EPS 15c, consensus 8c

Mar 11 2025Business Insider